Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Regulus Therapeutics Inc. RGLS
$1.78
+$0.05 (2.60%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
28796913.00000000
-
week52high
3.40
-
week52low
0.76
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.53252500
-
EPS
-1.84000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 02 сент 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 14 мая 2021 г. |
| Wells Fargo | Market Perform | Market Perform | 25 ноя 2020 г. |
| HC Wainwright & Co. | Buy | 25 ноя 2020 г. | |
| H.C. Wainwright | Buy | 25 ноя 2020 г. | |
| Canaccord Genuity | Buy | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Aker Christopher Ray | A | 45000 | 45000 | 11 янв 2023 г. |
| Hagan Joseph P | A | 100000 | 100000 | 11 янв 2023 г. |
| Aker Christopher Ray | A | 30000 | 30000 | 11 янв 2023 г. |
| CALSADA CRISPINA | A | 45000 | 45000 | 11 янв 2023 г. |
| Collier Kathryn J | A | 90000 | 90000 | 09 июн 2022 г. |
| Huang Alice Shih-hou | A | 90000 | 90000 | 09 июн 2022 г. |
| BALTIMORE DAVID | A | 90000 | 90000 | 09 июн 2022 г. |
| PAPADOPOULOS STELIOS | A | 90000 | 90000 | 09 июн 2022 г. |
| Nunn Jason Raleigh | A | 90000 | 90000 | 09 июн 2022 г. |
| Witz Pascale | A | 90000 | 90000 | 09 июн 2022 г. |
Новостная лента
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
Zacks Investment Research
14 апр 2023 г. в 14:25
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 21:49
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO & Director Denis Drygin - Chief Scientific Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Operator Hello, and welcome to the Regulus Therapeutics Inc. Q3 2022 Earnings Conference Call. [Operator Instructions].
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Zacks Investment Research
13 сент 2022 г. в 13:32
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
Hot Penny Stocks to Know About Right Now? 3 to Watch
PennyStocks
13 сент 2022 г. в 06:00
Here's what you need to know about trading penny stocks on September 13th The post Hot Penny Stocks to Know About Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Regulus Therapeutics to Participate in Upcoming Investor Conferences
PRNewsWire
02 сент 2022 г. в 16:05
SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in two upcoming investor conferences.